On the latest episode of the podcast, Dementia Matters, host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials.
Month: January 2023
Dr. Nathaniel Chin discusses the FDA approval of Leqembi on WPR
Nathaniel Chin, MD, joined host Rob Ferrett on the call-in program “Central Time” on The Ideas Network of Wisconsin Public Radio. Chin discussed the recent FDA approval of the drug Leqembi (lecanemab) to help with early Alzheimer’s and answered callers’ questions.
Dr. Cynthia Carlsson discusses the FDA approval of Leqembi
Cynthia Carlsson, MD, MS, was recently interviewed by CBS 58 News in Milwaukee about the U.S. Food and Drug Administration (FDA)
approval of Leqembi (lecanemab), which showed a reduction of clinical decline in a study of people with early Alzheimer’s disease.
FDA approves Alzheimer’s disease drug lecanemab
On January 6, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.
Dr. Sanjay Asthana appointed to serve on the National Advisory Council on Aging
Sanjay Asthana, MD, is the founding director of the Wisconsin Alzheimer’s Disease Research Center (ADRC) and an internationally renowned researcher and leader in the field of Alzheimer’s disease. The US Secretary of Health and Human …
Dr. Ozioma Okonkwo appointed to NIA-AA Alzheimer’s workgroup
Ozioma Okonkwo, PhD, has been appointed to participate in a National Institute on Aging (NIA) Alzheimer’s and Alzheimer’s Association workgroup, establishing the definition and classification of Alzheimer’s disease.